NYSE: $MRK A Significant Update for Pulmonary Arterial Hypertension Treatment The U.S. Food and Drug Administration (FDA) has officially approved a label update for Winrevair (sotatercept-csrk), marking a meaningful step forward in the treatment of pulmonary arterial hypertension (PAH). This update incorporates clinical data from the Phase 3 HYPERION trial, providing healthcare providers and patients…